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DOI: http://dx.doi.org/10.1016/j.hemonc.2013.08.005HematolDocetaxel belongs to the taxane family of anti-cancer drugs, which are commonly used in non-
small cell lung cancers. They stabilize microtubules by preventing depolymerization, resulting in
cell death. Pneumonitis is an uncommon side effect of docetaxel. We report a case of docetaxel
induced hypersensitivity pneumonitis mimicking lymphangitic carcinomatosis in a patient with
metastatic adenocarcinoma of the lung.54-year-old man was diagnosed with metastatic
adenocarcinoma of the lung in February 2012.
He presented with multiple brain metastases
which were found to be from his primary lung adeno-
carcinoma. EGFR (epidermal growth factor receptor)
on the cancer cells was wild-type, and ALK (anaplas-
tic lymphoma kinase) was not detected. He received
whole brain radiation therapy (3000 cGy) for his
brain metastasis. He was subsequently started on cis-
platin 75 mg/m2 and pemetrexed 500 mg/m2 every
3 weeks. He received three cycles of this chemother-
apy regimen from April 2012 to June 2012. Repeat
imaging at the end of this cycle revealed progression
of the disease in his lungs. The chemotherapy was
subsequently changed to docetaxel 75 mg/m2 every
3 weeks. He received four cycles of docetaxel from
July 2012 to October 2012. At this time he presented
to the clinic with extreme shortness of breath. On
examination, patient had cyanosis; his oxygen satura-
tion was 70% on room air. He had diffuse rales bilat-
erally on chest examination. He also had a rash on his
arms (Figure 1). A chest X-ray (Figure 2) and a CT
scan of his chest (Figure 3) were ordered, and patient
was admitted to the hospital. He was started on oxy-
gen initially at the rate of 6 L/min via a nasal cannula.
He was not able to maintain his oxygen saturation on
a nasal cannula, was switched to a non-rebreatherOncol Stem Cell Ther 6(3–4) Fourth Quarter 2013 hemoncstem.edmgr.mask, and subsequently to non-invasive positive pres-
sure ventilation. He was also started on broad spec-
trum antibiotics and intravenous steroids. The chest
X-ray and CT scan of the chest were read by the radi-
ologist as diffuse interstitial pneumonitis suspicious
for lymphangitic carcinomatosis. This was the initial
diagnosis for the patient, and given the fact that he
had metastatic adenocarcinoma of the lung to begin
with and had failed ﬁrst line chemotherapy, this was
thought to be the most likely diagnosis.
During the course of his hospitalization the patient
improved signiﬁcantly and was discharged from the
hospital in 10 days. He took steroids for 4 weeks.
His repeat CT scan in January 2013 (Figure 4)
showed marked improvement in his lung markings.
He was initially oxygen dependent but is off oxygen
at present. All these changes were attributed to doce-
taxel and he has been off docetaxel since October
2012 with the latest imaging done in March 2013
revealing slight progression of disease.DISCUSSION
Docetaxel is a taxane antineoplastic agent with activity
against a broad range of cancers. The side effects
commonly associated with docetaxel include myelo-
suppression, alopecia, asthenia, neurosensory problems,com 117
Figure 1. Macular papular rash with associated erythema on the
extensor surface of arm.
Figure 2. Chest X-ray showing prominent interstitial markings
bilaterally
Figure 3. CT chest showing increased reticular and nodular interstitial
density in both lungs and a cavitatory lesion in right lung.
Figure 4. Repeat CT chest showing marked improvement in the
previous interstitial markings.
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uncommon with docetaxel partly because docetaxel
is mixed in ethanol and water rather than cremophor,
and partly because it is given with steroids.1,2
There are several Phase II studies of single-agent
docetaxel which report Grade 4 toxicities in individual
patients as unexplained pneumonitis,3 fever, bilateral
pneumonia, severe hypoxia,4 or interstitial pneumo-
nia.5 More severe cases of interstitial pneumonitis
have been reported in patients treated with aHematodocetaxel and gemcitabine combination,6 and doce-
taxel administered with concomitant thoracic radia-
tion therapy.7 However, pulmonary toxicity induced
by docetaxel is extremely rare, and only a few cases
have been reported in the literature.8,9
The exact mechanism of docetaxel-induced inter-
stitial pneumonitis is not known, but both allergic
and the cell-mediated cytotoxic reactions have been
suggested.10 The docetaxel-induced lung toxicity in
the cases that have been reported usually occurred
after the second to fourth course of chemotherapy,
and was usually relieved with corticosteroid therapy.
6 Therefore, the involvement of a cytotoxic T-cell-
mediated mechanism is very likely. Interestingly, therel Oncol Stem Cell Ther 6(3–4) Fourth Quarter 2013 hemoncstem.edmgr.com
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seems to be a positive relationship between the tumor
response and the lung injury.
Although pneumonitis secondary to docetaxel is a
rare side effect, the mortality rate is high. Oncologists
should be aware of this complication. The patients
usually present with a high fever, cough, dyspnea,
and diffuse lung inﬁltration. The symptoms develop
acutely over 1–2 days and rapidly progress despite
empiric antibiotic therapies, and culminate in respira-
tory failure, which sometimes requires mechanicalHematol Oncol Stem Cell Ther 6(3–4) Fourth Quarter 2013 hemoncstem.edmgr.ventilation.10 The treatment of choice is the adminis-
tration of corticosteroid therapy, usually 30–60 mg of
prednisone per day for 2–3 weeks, or 60–240 mg per
day in more severe conditions such as acute respira-
tory failure with a slow and careful tapering-off
period.11 Our patient needed non-invasive ventilation
and responded well to steroids and antibiotic therapy.
His maculopapular rash, possibly from a similar
hypersensitivity reaction to docetaxel, also responded
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